Thanks for the link.

While the paper is from 2023, the study that it cites giving a 33% 5-year overall survival for bone metastatic prostate cancer is from 2007 (likely based on even-earlier data), before the widespread introduction of androgen-reception blockers (like Erleada) and long before treatments for oligometastatic and full-metastatic prostate cancer pioneered by Dr Kwon at Mayo and other oncologists.

Fortunately for all of us here, our options have improved a lot in 16+ years. If I'd been diagnosed even 5 years earlier (than 2021), my prospects would have been much-less encouraging.

(Former university prof here, so I always read the footnotes. 🙂 ).